




Eosinophils staining




Supplementary Figure 1: Hematoxylin and eosin staining for the eosinophils in tissue sections of Untrd, MNs-Der p1, MNs-Der p1+CpG, SCIT, Der p1 challenge and naïve mice groups.




MNs-Der p1+CpG





SCIT



Der p1 challenge



Naïve mice



SUPPLEMENTARY TABLE

Supplementary Table 1: Treatment groups and doses

Groups	Vaccination	Sensitization [†]	Challenge [‡]	Comment
Untrd	Untreated group that received MNs that were not coated with Der p1	✓	✓	Negative control, expected to induce high inflammation
MNs-Der p1	Der p1 coated MNs (25 µg Der p1)	✓	✓	Test group to study efficacy of MNs
MNs-Der p1+CpG	Der p1+CpG coated MNs (25 µg Der p1+25 µg CpG)	✓	✓	Test group to study effect of CpG as an adjuvant
SCIT	Der p1 (25 µg)+Alum (250 µg)	✓	✓	Positive control to mimic clinically approved subcutaneous allergy immunotherapy procedure
Der p1 challenge	✗	✗	✓	Negative control to assess effect of Der p1 challenge on naïve mice
Naive	✗	✗	✗	Negative control (without any treatment)

[†]**Sensitization:** Two doses each containing 25 µg Der p1 + 2 mg alum through intraperitoneal route at weekly intervals

[‡]**Challenge:** 50 µg Der p1 through the nasal route given on three consecutive days